Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 477 clinical trials
A Randomized Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)

fibrosis
vasectomy
hcv infection
hepatitis b surface antigen
fatty liver
  • 0 views
  • 05 Aug, 2020
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

This is an open-label, randomized study comparing a monitored ketogenic diet intervention using standard ketogenic diet (SKD) and standard of care (SOC) dietary recommendations for 16 weeks. Subjects enrolled in the standard of care group will receive a voucher to Weight Watchers after study completion.

cirrhosis
ketogenic diet
fatty liver
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects.

fibrosis
vcte
fibroscan
fatty liver
hepatic fibrosis
  • 0 views
  • 05 Aug, 2020
To Evaluate the Safety Tolerability PK and PD of XW003 Injection in Healthy Adult Participants

XW003 is an acylated human GLP-1 analogue and is being development for obesity management. This is a first-in-human (FIH), single-centre, double blind, randomised, SAD study of XW003 conducted in healthy adult participants. The study is designed to evaluate the safety, tolerability, PK, and PD of XW003 in healthy participants.

glucagon-like peptide 1
glp-1
drug test
glucagon-like peptide-1
  • 0 views
  • 16 Feb, 2024
  • 1 location
The European NAFLD Registry

The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. The ultimate goals are to better understand the drivers of interpatient variation in disease pathophysiology and severity and to …

metabolic syndrome
hba1c
nafld
fatty liver
alcoholic fatty liver
  • 0 views
  • 16 Feb, 2024
  • 37 locations
PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies

The main aim of the study is to set up an observational cohort with NAFLD (Non-alcoholic fatty liver disease) at different stage of disease (from simple steatosis to cirrhosis and/or HCC-Hepatocellular carcinoma) and for comparative purpose a cohort of subjects with diabetes and/or obesity and/or other risk factors (i.e. psoriasis, …

metabolic syndrome
nonalcoholic fatty liver
fatty liver
hepatitis c
inflammatory bowel disease
  • 0 views
  • 16 Feb, 2024
  • 1 location
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology as Reference

This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.

fibrosis
magnetic resonance elastography
MRI
elastography
steatohepatitis
  • 0 views
  • 05 Aug, 2020